AL 335

Drug Profile

AL 335

Alternative Names: AL-335; ALS-335; Uridine analogue - Alios BioPharma

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Alios BioPharma
  • Developer Alios BioPharma; Janssen
  • Class Antivirals; Pyrimidine nucleotides; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 20 Dec 2016 Janssen plans a phase II clinical trial in Hepatitis C (Combination therapy) in Japan (PO) (NCT02993250)
  • 01 Dec 2016 Phase-II clinical trials in Hepatitis C (Combination therapy) in Japan (PO) (NCT02993250)
  • 04 Oct 2016 Medivir plans an extension study to phase IIa trial in Hepatitis C (Combination therapy, Treatment naive)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top